Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Dulaglutide vs Pectin: Dulaglutide has the stronger overall evidence (7 vs 5.7/10); they're alternatives for manage blood sugar — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Dulaglutide wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
Top outcomes
Verdict
Too few graded studies
Top outcomes
Shared outcomes (2)
Outcomes where both Dulaglutide and Pectin have evidence — compare verdict strength side-by-side.
Prescription-only, clinician-prescribed. Subcutaneous 0.75 mg once weekly to start, usually escalated to 1.5 mg; 3.0 mg and 4.5 mg once-weekly doses are available for additional glycemic lowering. DO NOT self-dose.
Any time of day
Subcutaneous once-weekly pen (Trulicity)
6-15g of pectin daily, split across meals with water
With main meals, With a full glass of water, Split across the day (e.g. 2-3 doses)
Powder mixed in water or food
Weeks to months
Months to years
Months
Especially during initiation/escalation
3-4 weeks
Same meal
30-120 minutes
First 1-2 weeks
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Lancet (2019) · Rct · n=9901
Multicentre, double-blind, placebo-controlled cardiovascular-outcomes RCT: 9,901 patients aged ≥50 with type 2 diabetes, randomized to subcutaneous dulaglutide 1.5 mg/week or placebo at 371 sites in 24 countries
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Lancet Diabetes Endocrinol (2019) · Meta analysis
Meta-analysis of seven GLP-1 receptor agonist cardiovascular-outcomes trials (ELIXA, LEADER, SUSTAIN-6, EXSCEL, Harmony Outcomes, REWIND, PIONEER 6); 56,004 participants
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
Lancet (2019) · Rct · n=9901
Pre-specified exploratory analysis of the REWIND trial (9,901 participants) examining the renal component of the composite microvascular outcome
Cholesterol-lowering effects of dietary fiber: a meta-analysis
The American journal of clinical nutrition (1999) · Meta analysis
Meta-analysis of 67 controlled trials directly tested pectin, oat bran, guar gum, and psyllium against blood lipids.
Metabolic and Cardiovascular Benefits of Apple and Apple-Derived Products: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Frontiers in nutrition (2022) · Systematic review
Eighteen RCTs of whole apple, apple extract, and apple juice — key dietary sources of pectin — were pooled across nine cardiometabolic outcomes.
Systematic review of the mechanisms and evidence behind the hypocholesterolaemic effects of HPMC, pectin and chitosan in animal trials
Food chemistry (2016) · Systematic review
Systematic review of animal trials examining the cholesterol-lowering mechanisms of HPMC, pectin, and chitosan.
From a meta-analysis of 67 controlled trials of soluble fibres (PMID 9925120): across 2 to 10 g a day, each gram lowered total cholesterol by 0.045 mmol/L and LDL by 0.057 mmol/L, with pectin no different from oat or psyllium fibre, so 3 g is about 0.13 mmol/L and 10 g about 0.45 mmol/L of total cholesterol. The authors call the effect small within the practical range of intake. In healthy people with normal cholesterol, 12 g of pectin a day for 4 weeks did not change cholesterol (PMID 2992264). The relationship was modelled only up to 10 g.
AI-estimated from published studies. Interpret as directional guidance.
Dulaglutide has a higher evidence score (7/10 vs 5.7/10) and wins in 2 of 3 categories.
For manage blood sugar, Dulaglutide has a higher relevance score (82 vs 62).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.